INVIVYD INC

Investor insight: Mina Michael’s new Invivyd option grant signals executive confidence and long‑term alignment, hinting at future upside if clinical milestones hit.

Insider trades show Invivyd execs buying while selling to cover taxes—less than 0.5% dilution—signaling confidence ahead of LIBERTY Phase 3 results.

Invivyd insiders’ synchronized stock‑option buys signal confidence; CFO’s 625k‑share grant and 2.8M options suggest the company may rebound to $3.07 after key COVID‑19 antibody milestones.